Methane production

Methane-producing microbes are one possible contributor to persistent constipation. Their abundance in stool and the gas they release in breath have both been associated with slower bowel transit. But those are different measurements, and neither establishes why you're constipated.

This stool marker estimates your gut microbial community's capacity to produce methane from its microbial DNA. It remains an exploratory measurement, with no universally standardized clinical cutpoints or established treatment target. Its value is possible biological context for your symptoms; testing it has not been shown to improve constipation outcomes.

What a Stool Result Measures

Methane is a colorless, odorless gas produced in the gut mainly by archaea. Archaea are single-celled organisms from a separate branch of life from bacteria. Those that make methane are called methanogens. Methanobrevibacter smithii is a prominent human gut methanogen, but several other species contribute.

M. smithii can use hydrogen and carbon dioxide released when other microbes break down food. Other gut organisms also use hydrogen, including some bacteria that produce hydrogen sulfide. These groups can coexist, so having more methanogens doesn't necessarily mean you have fewer hydrogen sulfide producers.

The stool result summarizes methane-producing potential from the relative abundance of methane-producing microbes. It doesn't directly measure gas production or give an absolute count of all methanogens in your intestine. Actual gas output also depends on the food available to these microbes, their activity and conditions inside the gut.

A breath test measures methane that has entered the blood and reached the lungs. Most clinical methane research uses this breath measurement. Other studies measure the DNA of M. smithii alone in stool, which is narrower than this community-level estimate.

Studies comparing stool M. smithii measurements with breath methane have found correlations between them. That supports a biological connection, but the diagnostic accuracy reported for a particular species-counting method cannot be assigned to this stool marker. Stool production potential, a species count and breath methane cannot be converted into one another.

Methanogens are common inhabitants of healthy guts. Estimates that roughly a third to half of healthy adults are methane producers usually refer to detectable breath methane. They don't describe how many people carry any methane-producing microbes, which can be present even when breath methane is low.

Constipation and Slow Transit

The clearest clinical association is between breath methane and constipation, particularly slow passage through the colon. In one study of chronic constipation without irritable bowel syndrome, 75% of people with slow colonic transit produced methane on breath testing, compared with 28% of healthy controls. Methane was associated with transit time but not stool consistency in that study.

Irritable bowel syndrome, or IBS, involves recurrent abdominal pain associated with changes in bowel habits. A pooled analysis found about three times the odds of a methane-positive breath test in constipation-type IBS compared with diarrhea-type IBS. IBS as a whole was not associated with more methane positivity than healthy controls. The studies used varying methods, and the authors rated the evidence quality as low.

There is related stool evidence. One study found more M. smithii DNA in constipation-type IBS than in diarrhea-type IBS, with higher counts associated with breath methane. Another study found that greater breath methane in people with IBS was associated with fewer bowel movements and harder stools. These findings concern specific stool organisms or breath gas, rather than validation of this stool production estimate.

The association also appears in some children. In an older study, 65% of children with constipation and fecal soiling produced breath methane, compared with 15% of matched controls. Children with constipation without soiling did not show the same clear difference. The finding shouldn't be extended to every child with constipation.

Which Comes First, the Microbes or the Slow Gut?

Methane may contribute to slow transit, while slow transit may also favor the microbes that produce it. Human observational studies cannot reliably separate those directions. Food moving slowly through the colon changes the environment in which microbes grow.

Animal experiments support a direct effect of methane on gut movement. In a mouse study, a methane-consuming bacterium reduced methane and reversed methane-associated slowing of intestinal movement. This has not established that giving the organism to people treats constipation or lowers a stool estimate of methane-producing microbes.

Human findings are less uniform. A study of 103 people with IBS and 28 healthy controls compared breath methane with gas collected from the rectum. Breath testing missed many people who produced methane in the colon, and colonic methane production was not associated with IBS symptoms or transit time.

Studies comparing stool with samples from the colon lining also found different relationships with constipation, transit and methane. A stool sample captures one part of the intestinal microbial community. It cannot establish where methanogens live or whether they are causing your symptoms.

Lower Levels, Diarrhea and Inflammatory Bowel Disease

Lower methane-producing potential is not a diagnosis or a deficiency. Breath methane and stool methanogens have been less common in some groups with diarrhea or intestinal inflammation, but these are population associations.

In controlled studies pooled in a systematic review, about 7% of people with inflammatory bowel disease were methane-positive on breath testing, compared with about 24% of healthy controls. Methane positivity was also less common in Crohn's disease than ulcerative colitis. Those breath findings do not establish a stool threshold for detecting either condition.

Research combining stool analysis with breath gases has linked constipation-type IBS with methanogens and diarrhea-type IBS with some hydrogen sulfide-producing bacteria, including Desulfovibrio. Finding one of these organisms doesn't establish how much gas it produces or whether it explains your bowel symptoms.

Weight, Blood Sugar and the Liver

Findings about body weight point in different directions. In 1,647 people with functional digestive disorders, breath methane was mostly associated with lower measures of body size. In a separate study of 792 adults referred for breath testing, people positive for both hydrogen and methane had higher body mass index and body fat.

Stool studies have also varied. In a cohort of 472 school-age children, the group with the highest M. smithii counts had greater odds of overweight than children without detectable M. smithii. Another small study found higher stool M. smithii counts in people with anorexia nervosa than in lean controls. Whether this reflected low food intake, slow transit or another feature of the illness was not established.

Some newer studies have linked breath methane with metabolic illness. Among 2,549 people with metabolic fatty liver disease and digestive symptoms, methane-positive breath testing became more common with more advanced liver fibrosis. In another study of 503 people undergoing breath testing, the methane-predominant group had higher fasting glucose. Both studies examined associations at one point in time.

These findings don't establish that this stool result predicts diabetes, weight gain or liver disease. They also don't show that reducing methane-producing potential prevents those conditions.

Cancer Risk

Older breath studies reported more methane production in people with colorectal cancer, while comparisons across Southern African populations found no consistent relationship between methane prevalence and population cancer rates. Neither approach established that methane causes cancer. A stool methane-production estimate has no validated role in colorectal cancer screening or personal cancer-risk prediction.

Tracking Your Result Over Time

A study taking stool samples four weeks apart found groups with consistently higher or lower methanogen levels, although some relationships with symptoms varied between sampling times. The often-cited study spanning 35 years was small and measured breath methane, not stool methanogens. It suggests methane-producing status tends to be stable but doesn't show how much this stool marker varies for you.

There is no established size of change in this stool marker that represents meaningful improvement in constipation. A lower result can accompany changes in the microbial community without proving that methane production fell or that the cause of your symptoms was treated.

When Results Can Be Misleading

• Potential versus activity: microbial DNA supports an estimate of production capacity. It doesn't establish how active the organisms were or how much methane they released.
• Relative abundance: a group's share of the microbial community can change because other organisms increased or decreased. A change in that share is not necessarily a matching change in its absolute population.
• Stool versus the rest of the gut: stool doesn't reveal where methanogens live or fully represent organisms attached to the intestinal lining.
• Bowel transit: the speed at which stool moves through the colon can affect microbial composition, making it difficult to separate a cause of constipation from a consequence.
• Recent treatment: antibiotics and other changes affecting the gut can alter its microbial community. Different treatments need not change stool methanogens and breath methane in the same way.
• Laboratory differences: DNA extraction, sequencing, analysis and comparison populations can affect results. Values and report categories from different methods aren't interchangeable.
• Sample handling: contamination, unsuitable storage or delayed processing can affect a stool DNA profile.